Lapatinib Ratiopharm

Lapatinib, the active ingredient in Lapatinib Ratiopharm, is a tyrosine kinase inhibitor presented as a tablet for oral use. It targets HER2‑positive metastatic breast cancer and is prescribed for adult patients whose tumors overexpress the HER2 receptor and is used under specialist supervision.

GNH USA supplies Lapatinib Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable sourcing for hospitals, pharmacies and clinical trial sites through regulated distribution channels.

Lapatinib is a tyrosine kinase inhibitor used in the management of HER2‑driven cancers.

- HER2‑positive metastatic breast cancer: used in combination with capecitabine to delay disease progression. - HER2‑positive advanced breast cancer after prior therapy: may be combined with trastuzumab to enhance response. - HER2‑positive gastric adenocarcinoma (in approved regions): used with chemotherapy to improve tumor control.

Lapatinib may cause a range of adverse reactions, some of which are common and others that are serious or rare.

Common Side Effects: - Diarrhea: frequent loose stools, may require supportive care. - Rash: skin erythema often on trunk or extremities. - Nausea: mild to moderate, may improve with food. - Fatigue: generalized tiredness affecting daily activities. - Hand‑foot syndrome: redness or swelling of palms and soles. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Cardiac dysfunction: decreased left‑ventricular ejection fraction. - Interstitial lung disease: cough, dyspnea, and infiltrates. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients for specific risks.

- Liver function monitoring: obtain baseline transaminases and repeat periodically. - Cardiac assessment: perform echocardiogram or MUGA scan before and during treatment. - Avoid in severe hepatic impairment: contraindicated in patients with Child‑Pugh C. - Caution with QT‑prolonging agents: monitor ECG if co‑administered. - Pregnancy and lactation: safety not established; avoid use. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lapatinib interacts with several medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise lapatinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antacids that raise gastric pH: can decrease absorption.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., statins, midazolam): may require dose adjustment. - Warfarin: monitor INR for altered anticoagulation. - Digoxin: observe for increased serum concentrations. - Hormonal contraceptives: efficacy may be reduced; consider alternative methods.